Fig. 4
From: CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease
No behavioral abnormalities 10 weeks after injection of AAV-CERTL. a The effects of CERTL over-expression were investigated in 30 5xFAD and 30 WT males. Mice were bilaterally injected at 12–13 weeks of age with AAV-CERTL or AAV-control particles at the dose 1.12 × 10E8 transducing unit (t.u.). Starting at week 22 of age, animals were challenged with the following behavioral tests: open field (OF) for locomotion activity, alternate Y-maze (AYM) and spatial Y-maze (SYM) for spatial memory, and elevated zero-maze (EZM) for anxiety. b Locomotion expressed as distance traveled in OF task. c The graph shows the results of the working memory in the AYM task as a percentage of correct alternation in the first four triads. Percentage were compared to 50% chance levels (one sample t test **p < 0.01). d Anxiety was assessed, measuring the percentage of time spent in the closed arm in EZM. e Memory was measured in SYM expressed as a percentage of time spent in the novel arm. Bars represent the means ± S.E.M per group N = 10–20 (two-way ANOVA, interaction effect F = 4.170 p = 0.0463, LSD, *p < 0.05)